Selection of risk and diagnosis in diabetic polyneuropathy. Validation of method of new systems;Selección de riesgo y diagnóstico de la polineuropatía diabética. Validación metodológica de nuevos sistemas

Atencion Primaria

Volumn 38, Issue 2, 2006, Pages 116-121

  Jurado, Jerónimo ^a   Caula, Jacinto ^a   Pou I Torelló, Josep Maria ^b  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Diabetic polyneuropathy; Diagnosis; Prevention; Risk; Selection

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIAGNOSTIC PROCEDURE; ELECTRODIAGNOSIS; ELECTROMYOGRAM; HUMAN; INFLAMMATION; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; POPULATION; PRIMARY MEDICAL CARE; RETINOPATHY; RISK; SENSITIVITY ANALYSIS; VALIDATION STUDY; VASCULAR DISEASE;

EID: 33746985534     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090436     Document Type: Article

References (26)

1. Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, Zagari M. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther. 1998;20:169-81.
2. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994;331:854-60.
3. Mayfield JA, Reiber GE, Sanders LJ, Cped DJ, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care. 1998;21:2161-77.
4. Ollendorf DA, Kotsanos JG, Wishner WJ, Friedman M, Cooper T, Bittoni M, et al. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care. 1998;21:1240-5.
5. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790-5.
6. Boulton AJ, Vileikyte L. The diabetic foot: the scope of the problem. J Fam Pract. 2000;49 11 Suppl:S3-8.
7. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
8. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tigorviste C, et al, for the EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341-50.
9. Vinik AI, Erbas T, Park TS, Stansberry KB, Scaneffi JA, Pittenger GL. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1468-75.
10. American Diabetes Association, American Academy of Neurology. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care. 1988;11:592-7.
11. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281-9.
12. Meijer JW, Bosma E, Lefrandt JD, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care. 2003;26:697-701.
13. Young MJ, Boulton AJM, Macleod AK, et al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150-4.
14. Bril V. NIS-LL. The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol. 1999;41 Suppl 1:8-13.
15. Bril V, Perkins BA. Validation of the Toronto scoring system for diabetic polyneuropathy. Diabetes Care. 2002;25:2048-52.
16. Shy ME, Frohman EM, So YT, Arezzo JC, Cornblath DR, Giuliani Z. Quantitative sensory testing. Neurology. 2003; 60:898-904.
17. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score. Validation and reliability study. Neurology. 1999;53:1660.
18. Pham H, Amstrong D, Harvey C, Harkless L, Giurini J, Veves A. Screening Techniques to identify people at high risk for diabetic foot ulceration. A prospective multicenter trial. Diabetes Care. 2000;23:606-11.
19. Perkins B, Olaleye D, Zinman B, Bril V. Simple screening for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24:250-6.
20. Jurado J, Ybarra J, Pou JM. The North Catalonia Diabetes Study (NCDS): use of vibration perception thresholds and sw monofilament for diabetic polyneuropathy diagnosis in primary care (abstract). Diabetes. 2005;54:A68.
21. Jurado J, Noguer L, Brossa N, et al. The North Catalonia Diabetes Study (NCDS): diabetic polyneuropathy and foot risk. Diabetologia. 2003;46 Suppl 2:A3-4.
22. Cabezas Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. For the Neuropathy Study group of the Spanish Diabetes Society (SDS). Diabetologia. 1998;41:1263-9.
23. Acosta J, Qin X, Halperin J. Complement and complement regulatory protein as a potential molecular targets for vascular diseases. Curr Pharm. 2004;10:203-11.
24. Aarli A. Role of cytokines in neurological disorders. Curr Med Chem. 2003;10:193-7.
25. Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Int J Exp Diabesity Res. 2003;4:65-71.
26. Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy from glucose metabolism to neurodegeneration. Int J Exp Diabesity Res. 2003;4:303-12.